This Week’s Biopharma News: Big Moves in Bispecifics - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

Clinical Scorecard: This Week’s Biopharma News: Big Moves in Bispecifics

At a Glance

CategoryDetail
ConditionAdvanced squamous non-small cell lung cancer
Key MechanismsPD-1/VEGF bispecific antibody
Target PopulationPatients with advanced squamous NSCLC
Care SettingOncology

Key Highlights

  • median_survival_rates
  • adverse_events

Guideline-Based Recommendations

Diagnosis

    Management

    • Ivonescimab plus chemotherapy as first-line treatment for advanced squamous NSCLC based on HARMONi-6 trial results.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Adults with advanced squamous NSCLC.

        Ivonescimab shows significant survival benefits compared to standard therapies.

        Clinical Best Practices

        • Consider ivonescimab for patients not responding to standard PD-1 therapies.
        • Regularly assess patient response and adverse events during treatment, including specific monitoring for grade 3 or higher events.

        Related Resources & Content

        Original Source(s)

        This Week’s Biopharma News: Big Moves in Bispecifics

        • June 9, 2026

        Related Content

        A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

        Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

        • by

        • September 24, 2026

        • 11 min
        Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

        Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer